CaroGen
CaroGen is a biotechnology company developing investigational immunotherapies based on its AVIDIO virus-like vesicle platform. Its lead candidate, CARG-201, targets chronic hepatitis B and is being prepared for a first-in-human Phase 1/1b study. Oncology applications of the platform, including CARG-2020, are exclusively licensed to the independent spinout Viridion Therapeutics. CARG-201 has not been approved for use by any regulatory authority.
Key facts
| Legal Name | CaroGen Corporation |
|---|---|
| Company Operating Status | Active |
| Full Address | 400 Farmington Ave Farmington, CT 06032 |
| Public/Private | Private |
| Wellfound ID | carogen |
Contact details
Email and phone for CaroGen are available to signed-in members of CliffBio.
Sign in to view